A few NKG2D-based CAR therapies are described, with anti-mesothelin-NKG2D-2B4 CARs showing the best results regarding anti-tumor response, proving the potential of 2B4 as the co-stimulatory domain in CAR constructs (reviewed in [181]). This evidence concerns the gene KLRK1 and neoplasm.